Related Experiment Video
Updated: Aug 15, 2025
08:29
Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
Published on: December 18, 2016
14.1K
Pathogenesis of Dementia
1Jerzy Kukuczka Academy of Physical Education, 72 Mikołowska Street, 40-065 Katowice, Poland.
International Journal of Molecular Sciences
|January 8, 2023
Summary
Dementia affects 55 million globally, characterized by cognitive decline. This review explores energy and cognitive metabolism dysfunction in aging brains as a potential cause for dementia and Alzheimer's disease.
Area of Science:
- Neuroscience
- Gerontology
- Metabolic Disorders
Background:
- Dementia impacts 55 million worldwide, with Alzheimer's disease being the most common form.
- Current treatments for dementia focus on symptom management rather than addressing underlying causes.
- Neurodegenerative disorders like dementia and Parkinson's disease are associated with aging.
Purpose of the Study:
- To review the etiology of dementia and Alzheimer's disease.
- To explore the role of energy and cognitive metabolism dysfunction in the aging brain.
- To propose new preventive and therapeutic strategies for neurodegenerative disorders.
Main Methods:
- Narrative review of existing literature.
- Analysis of the relationship between aging, metabolism, and neurodegeneration.
- Exploration of energy metabolism and cognitive function in the brain.
Main Results:
- Dementia involves progressive impairments in memory, thinking, and behavior due to brain damage.
- Alzheimer's disease is characterized by significant cognitive deficits, including memory loss and impaired judgment.
- Existing treatments have failed to address the root causes of dementia.
Conclusions:
- Dysfunction in energy and cognitive metabolism may be central to aging-related neurodegenerative diseases.
- Understanding these metabolic disruptions could lead to novel therapeutic approaches.
- This perspective may advance the development of strategies to combat dementia, Alzheimer's disease, and Parkinson's disease.
Keywords:
Alzheimer’s diseasebrain agingbrain energy metabolismcognitive metabolismdementianeurodegenerative disordersMore Related Videos
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
10.3K
07:57An Alternative Approach to Study Primary Events in Neurodegeneration Using Ex Vivo Rat Brain Slices
Published on: April 11, 2018
7.0K
Related Concept Videos
01:30Dementia
153
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
153
01:26Alzheimer's Disease: Overview
600
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
600
01:27Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
831
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
831
01:15Parkinson's Disease: Overview
645
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
645
01:28Disorders of the Nervous Tissue
1.5K
Nervous tissue is a vital component of the human body's communication system, enabling us to perceive and respond to stimuli. However, like all other tissues, it is vulnerable to disorders and diseases that can significantly impact our neurological functioning.
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
1.5K
01:22Alzheimer's Disease: Treatment
238
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
238